Anne Katrin Külz1, Sarah Landmann2, Barbara Cludius3, Birgit Hottenrott4, Nina Rose5, Thomas Heidenreich6, Elisabeth Hertenstein7, Ulrich Voderholzer8, Steffen Moritz9. 1. Clinic of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany. anne.katrin.kuelz@uniklinik-freiburg.de. 2. Clinic of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany. sarah.landmann@uniklinik-freiburg.de. 3. Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. b.cludius@uke.de. 4. Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. b.hottenrott@uke.uni-hamburg.de. 5. Clinic of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany. nina.rose@gmx.de. 6. Esslingen University of Applied Sciences, Esslingen, Germany. Thomas.Heidenreich@hs-esslingen.de. 7. Clinic of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany. elisabeth.hertenstein@uniklinik-freiburg.de. 8. Schoen Clinic Roseneck, Prien, Germany. UVoderholzer@Schoen-Kliniken.de. 9. Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. moritz@uke.de.
Abstract
BACKGROUND:Obsessive-compulsive disorder (OCD) is a very disabling condition with a chronic course, if left untreated. Though cognitive behavioral treatment (CBT) with or without selective serotonin reuptake inhibitors (SSRI) is the method of choice, up to one third of individuals with obsessive-compulsive disorder (OCD) do not respond to treatment in terms of at least 35% improvement of symptoms. Mindfulness based cognitive therapy (MBCT) is an 8-week group program that could help OCD patients with no or only partial response to CBT to reduce OC symptoms and develop a helpful attitude towards obsessions and compulsive urges. METHODS/ DESIGN: This study is a prospective, bicentric, assessor-blinded, randomized, actively-controlled clinical trial. 128 patients with primary diagnosis of OCD according to DSM-IV and no or only partial response to CBT will be recruited from in- and outpatient services as well as online forums and the media. Patients will be randomized to either an MBCT intervention group or to a psycho-educative coaching group (OCD-EP) as an active control condition. All participants will undergo eight weekly sessions with a length of 120 minutes each of a structured group program. We hypothesize that MBCT will be superior to OCD-EP in reducing obsessive-compulsive symptoms as measured by the Yale-Brown-Obsessive-Compulsive Scale (Y-BOCS) following the intervention and at 6- and 12-months-follow-up. Secondary outcome measures include depressive symptoms, quality of life, metacognitive beliefs, self-compassion, mindful awareness and approach-avoidance tendencies as measured by an approach avoidance task. DISCUSSION: The results of this study will elucidate the benefits of MBCT for OCD patients who did not sufficiently benefit from CBT. To our knowledge, this is the first randomized controlled study assessing the effects of MBCT on symptom severity and associated parameters in OCD. TRIAL REGISTRATION: German Clinical Trials Register DRKS00004525 . Registered 19 March 2013.
RCT Entities:
BACKGROUND:Obsessive-compulsive disorder (OCD) is a very disabling condition with a chronic course, if left untreated. Though cognitive behavioral treatment (CBT) with or without selective serotonin reuptake inhibitors (SSRI) is the method of choice, up to one third of individuals with obsessive-compulsive disorder (OCD) do not respond to treatment in terms of at least 35% improvement of symptoms. Mindfulness based cognitive therapy (MBCT) is an 8-week group program that could help OCDpatients with no or only partial response to CBT to reduce OC symptoms and develop a helpful attitude towards obsessions and compulsive urges. METHODS/ DESIGN: This study is a prospective, bicentric, assessor-blinded, randomized, actively-controlled clinical trial. 128 patients with primary diagnosis of OCD according to DSM-IV and no or only partial response to CBT will be recruited from in- and outpatient services as well as online forums and the media. Patients will be randomized to either an MBCT intervention group or to a psycho-educative coaching group (OCD-EP) as an active control condition. All participants will undergo eight weekly sessions with a length of 120 minutes each of a structured group program. We hypothesize that MBCT will be superior to OCD-EP in reducing obsessive-compulsive symptoms as measured by the Yale-Brown-Obsessive-Compulsive Scale (Y-BOCS) following the intervention and at 6- and 12-months-follow-up. Secondary outcome measures include depressive symptoms, quality of life, metacognitive beliefs, self-compassion, mindful awareness and approach-avoidance tendencies as measured by an approach avoidance task. DISCUSSION: The results of this study will elucidate the benefits of MBCT for OCDpatients who did not sufficiently benefit from CBT. To our knowledge, this is the first randomized controlled study assessing the effects of MBCT on symptom severity and associated parameters in OCD. TRIAL REGISTRATION: German Clinical Trials Register DRKS00004525 . Registered 19 March 2013.
Authors: C Spitzer; S Hammer; B Löwe; H J Grabe; S Barnow; M Rose; K Wingenfeld; H J Freyberger; G H Franke Journal: Fortschr Neurol Psychiatr Date: 2011-08-25 Impact factor: 0.752
Authors: Helen Blair Simpson; Jonathan D Huppert; Eva Petkova; Edna B Foa; Michael R Liebowitz Journal: J Clin Psychiatry Date: 2006-02 Impact factor: 4.384
Authors: Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu Journal: Am J Psychiatry Date: 2005-01 Impact factor: 18.112
Authors: H Blair Simpson; Michael R Liebowitz; Edna B Foa; Michael J Kozak; Andrew B Schmidt; Vivienne Rowan; Eva Petkova; Kevin Kjernisted; Jonathan D Huppert; Martin E Franklin; Sharon O Davies; Raphael Campeas Journal: Depress Anxiety Date: 2004 Impact factor: 6.505
Authors: Anne Katrin Külz; Sarah Landmann; Barbara Cludius; Nina Rose; Thomas Heidenreich; Lena Jelinek; Heike Alsleben; Karina Wahl; Alexandra Philipsen; Ulrich Voderholzer; Jonathan G Maier; Steffen Moritz Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-11-16 Impact factor: 5.270
Authors: Michael Kyrios; Claire Ahern; Daniel B Fassnacht; Maja Nedeljkovic; Richard Moulding; Denny Meyer Journal: J Med Internet Res Date: 2018-08-08 Impact factor: 5.428